Advantages of Technological Platforms
Youngen has developed a Fast Integrated Screening Technology called FlSTsiran that is uniquely positioned to rapidly identify RNA molecules with potent activity, long durability and superior safety.
Youngen has developed a Multi-targeted Single-entity Technology called MSTsiran that is capable of incorporating two or more different siRNAs. This technology could be applied to treat many complex diseases that are caused by the dysregulation of more than one gene or multiple diseases.
As a center for drug evaluation and center pharmaceutical platform, Youngen has developed a siRNA Transport Technology called STTsiran that can significantly enhance the activity of siRNA drugs in extra-hepatic tissues. This technology enables tissue specific targeting including the brain, muscle, and adipose.
If you want to know more about emergence of new technology, please visit our website.
As a medical tech company, we will do our best to meet all the needs of customers.
You must be logged in to post a comment.